Campiani Giuseppe, Butini Stefania, Trotta Francesco, Fattorusso Caterina, Catalanotti Bruno, Aiello Francesca, Gemma Sandra, Nacci Vito, Novellino Ettore, Stark Jennifer Ann, Cagnotto Alfredo, Fumagalli Elena, Carnovali Francesco, Cervo Luigi, Mennini Tiziana
Dipartimento Farmaco Chimico Tecnologico, Universitá di Siena, via Aldo Moro, 53100 Siena, Italy.
J Med Chem. 2003 Aug 28;46(18):3822-39. doi: 10.1021/jm0211220.
The synthesis, pharmacological evaluation, and structure-activity relationships (SARs) of a series of novel arylalkylpiperazines structurally related to BP897 (3) are described. In binding studies, the new derivatives were tested against a panel of dopamine, serotonin, and noradrenaline receptor subtypes. Focusing mainly on dopamine D(3) receptors, SAR studies brought to light a number of structural features required for high receptor affinity and selectivity. Several heteroaromatic systems were explored for their dopamine receptor affinities, and combinations of synthesis, biology, and molecular modeling, were used to identify novel structural leads for the development of potent and selective D(3) receptor ligands. Introduction of an indole ring linked to a dichlorophenylpiperazine system provided two of the most potent and selective ligands known to date (D(3) receptor affinity in the picomolar range). The intrinsic pharmacological properties of a subset of potent D(3) receptor ligands were also assessed in [(35)S]-GTPgammaS binding assays. Evidence from animal studies, in particular, has highlighted the dopaminergic system's role in how environmental stimuli induce drug-seeking behavior. We therefore tested two novel D(3) receptor partial agonists and a potent D(3)-selective antagonist in vivo for their effect in the cocaine-seeking behavior induced by reintroduction of cocaine-associated stimuli after a long period of abstinence, and without any further cocaine. Compound 5 g, a nonselective partial D(3) receptor agonist with a pharmacological profile similar to 3, and 5p, a potent and selective D(3) antagonist, reduced the number of active lever presses induced by reintroduction of cocaine-associated stimuli. However, 5q, a highly potent and selective D(3) partial agonist, did not have any effect on cocaine-seeking behavior. Although brain uptake studies are needed to establish whether the compounds achieve brain concentrations comparable to those active in vitro on the D(3) receptor, our experiments suggest that antagonism at D(2) receptors might significantly contribute to the reduction of cocaine craving by partial D(3) agonists.
本文描述了一系列与BP897(3)结构相关的新型芳基烷基哌嗪的合成、药理评价及构效关系(SARs)。在结合研究中,对这些新衍生物针对一组多巴胺、5-羟色胺和去甲肾上腺素受体亚型进行了测试。主要聚焦于多巴胺D(3)受体,构效关系研究揭示了高受体亲和力和选择性所需的一些结构特征。研究了几种杂芳族系统的多巴胺受体亲和力,并结合合成、生物学和分子建模来确定用于开发强效和选择性D(3)受体配体的新型结构先导物。引入与二氯苯基哌嗪系统相连的吲哚环产生了两种迄今为止已知的最有效和选择性的配体(D(3)受体亲和力在皮摩尔范围内)。还在[(35)S]-GTPγS结合试验中评估了一组强效D(3)受体配体的内在药理特性。特别是来自动物研究的证据突出了多巴胺能系统在环境刺激如何诱导觅药行为中的作用。因此,我们在体内测试了两种新型D(3)受体部分激动剂和一种强效D(3)选择性拮抗剂,以观察它们对长期禁欲后重新引入可卡因相关刺激(且无任何进一步可卡因)所诱导的觅可卡因行为的影响。化合物5 g是一种非选择性D(3)受体部分激动剂,其药理特性与3相似,而5p是一种强效和选择性D(3)拮抗剂,它们减少了重新引入可卡因相关刺激所诱导的主动杠杆按压次数。然而,5q是一种高效和选择性D(3)部分激动剂,对觅可卡因行为没有任何影响。尽管需要进行脑摄取研究来确定这些化合物是否能达到与体外对D(3)受体有活性时相当的脑浓度,但我们的实验表明D(2)受体拮抗作用可能对部分D(3)激动剂减少可卡因渴望有显著作用。